Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45,181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. Cohen RB, et al. Among authors: xu h. Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9. doi: 10.1007/s00280-006-0352-0. Epub 2006 Oct 10. Cancer Chemother Pharmacol. 2007. PMID: 17031646 Clinical Trial.
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Schöffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, Gerletti P, Xu H, Jakubczak JL, English PA, Pierce KJ, Burris HA. Schöffski P, et al. Among authors: xu h. Eur J Cancer. 2011 Oct;47(15):2256-64. doi: 10.1016/j.ejca.2011.07.008. Epub 2011 Aug 16. Eur J Cancer. 2011. PMID: 21852114 Clinical Trial.
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL. Infante JR, et al. Among authors: xu h. J Clin Oncol. 2012 May 1;30(13):1527-33. doi: 10.1200/JCO.2011.38.9346. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454420 Clinical Trial.
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA, Shaw AT, Camidge DR, Giaccone G, Shreeve SM, Tang Y, Goldberg Z, Martini JF, Xu H, James LP, Solomon BJ. Jänne PA, et al. Among authors: xu h. J Thorac Oncol. 2016 May;11(5):737-747. doi: 10.1016/j.jtho.2016.01.022. Epub 2016 Feb 18. J Thorac Oncol. 2016. PMID: 26899759 Free article. Clinical Trial.
45,181 results
You have reached the last available page of results. Please see the User Guide for more information.